Opzelura® 15 mg/g cream (ruxolitinib phosphate): Important information regarding presence of particles in Opzelura® cream

A Dear Healthcare Professional Letter has been issued by Rxilient Pte Ltd to inform healthcare professionals that small, visible crystal-like particles have been reported in Opzelura^® (ruxolitinib) cream. The particles might form out of the active ingredient (ruxolitinib, as the dihydrate). While these crystal-like particles may cause some discomfort to patients, they do not pose any significant safety risk to patients. The continued usage of the product, with the crystals like particles, over a short period of time is not expected to result in significant loss of efficacy of the treatment based on the available data. Healthcare professionals are advised to inform their patients of the possible presence of the particles and should they be present, to return the tube for a replacement. Please refer to the letter for details.

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of these letters can be found in the MOH Alert System, which is accessible via the Health Professionals Portal (HPP), a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://hpp.moh.gov.sg and follow the procedures below to access the MOH Alert system.

Step 1: Select your profession under ‘For Healthcare Professionals’.

Step 2: Click on ‘Useful links’.

Step 3: Click on ‘MOH Alert’ and log in via Singpass.

Step 4: Click on ‘Drug Alerts’ or ‘Med Device Alerts’ to view the DHCPLs.